Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
British Journal of Haematology|October 3, 2002
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survivalFrancis J Giles, Hagop M Kantarjian, B Nebiyou Bekele, et al.
Blood|August 1, 2002
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemiaAlessandra Ferrajoli, Michael J Keating, Taghi Manshouri, et al.
Cancer Cell|June 16, 2012
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancerJames G Jackson, Vinod Pant, Qin Li, et al.
Leukemia Research|May 4, 2004
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphomaFrancis J Giles, Julie M Vose, Kim-Anh Do, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cellsWarren Fiskus, Srdan Verstovsek, Taghi Manshouri, et al.
British Journal of Haematology|November 10, 2009
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)Gheath Alatrash, Maher Albitar, Susan O'Brien, et al.
British Journal of Haematology|February 13, 2003
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemiaWilliam G Wierda, Marcella M Johnson, Kim-Anh Do, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemiaMirna Golemovic, Srdan Verstovsek, Francis Giles, et al.
Blood|March 21, 2012
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcomeSu-Jiang Zhang, Raajit Rampal, Taghi Manshouri, et al.
Blood|July 1, 2015
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinibKeyur P Patel, Kate J Newberry, Rajyalakshmi Luthra, et al.
Pageof 9